Those numbers don't look very relevant to Anavex because if the MAA is approved (presumably everything in your model depends on this event) then $1 and $2 and $5 are crazy low. And for pre-revenue biopharma, discount rates are usually far higher. But where everything is essentially dependent on a single event, this kind of modeling is not very useful.
More useful, IMO, is the value of 3-71 P2b readout and the MAA decision. The former is a big deal but we are not focused on it because of the much larger decision looming over it. Taken together, AVXL goes asymptotic which is why models and discount rates don't matter much (IMO, again.)
Market Data 
Markets 
AI
